research P163 : Clinical efficacy of 2.5mg/day finasteride in female pattern hair loss
2.5 mg/day finasteride effectively treats female pattern hair loss.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch P188 : Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: a retrospective case series study Department of Dermatology, Dongguk
Adipose stem cell-conditioned media improved hair density and thickness in women with hair loss.
research 698 Clinical analysis in young patient with persistent sexual dysfunctions after finasteride assumption to prevent male pattern hair loss
Finasteride for hair loss may cause long-lasting sexual side effects in young males.
research A Clinical Study of 50 Cases of Female Pattern Hair Loss
Genetics, low estrogen, and low iron levels contribute to female hair loss, with specific scalp signs indicating severity.
research A Clinical Study of Androgenetic Alopecia(IV)
research A Clinical Study of the Effects of Finasteride on Androgenetic Alopecia
Finasteride effectively treats hair loss in men with minimal side effects.
research Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
A multidisciplinary approach is crucial for safe and effective hormone treatment in gender-dysphoric individuals, with specific guidelines for adolescents and adults.
research Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.
research Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.